Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

JCL Bioassay Corp Amends Consolidated Full-year Outlook for FY 2013


Tuesday, 23 Apr 2013 02:50am EDT 

JCL Bioassay Corp announced that it has lowered the consolidated full-year outlook for revenue from JPY 2,391 million to JPY 2,163 million and operating profit (loss) from JPY 94 million to JPY (7 million), but has raised the consolidated full-year outlook for ordinary profit (loss) from JPY (18 million) to JPY 111 million, net profit (loss) from JPY (200 million) to JPY (137 million) and earning per share (loss) from JPY (60.50) to JPY (41.44) for the fiscal year ended March 31, 2013. The negative outlook for revenue and operating profit is mainly due to decrease of order. The positive outlook for ordinary profit and net profit is mainly due to the expected gain due to change in exchange rate. 

Company Quote

442.0
4.0 +0.91%
27 Aug 2014